Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29962730 | 1.00 | SLC22A12 (0.48) | SLC22A12METPOLBRPS6KA5KDM4E | |
| SCHEMBL20049419 | 0.79 | GABRG2 (0.43) | SLC22A12METPOLBKDM4EALDH1A1 | |
| SCHEMBL30935087 | 0.79 | ELANE (0.51) | POLBKDM4EGPR119BUB1BCHE | |
| SCHEMBL135567 | 0.79 | KMT2A (0.52) | KDM4EALDH1A1BCHEL3MBTL1 | |
| SCHEMBL31200457 | 0.78 | SLC22A12 (0.55) | SLC22A12METRPS6KA5RAPGEF4 | |
| SCHEMBL12685164 | 0.77 | POLB (0.41) | POLBKDM4EALDH1A1GPR119L3MBTL1 | |
| SCHEMBL16593587 | 0.77 | L3MBTL1 (0.43) | POLBKDM4EALDH1A1GPR119BCHE | |
| SCHEMBL8877952 | 0.77 | PARP1 (0.59) | SLC22A12POLBGPR119BUB1HSP90AA1 | |
| SCHEMBL28472077 | 0.77 | POLB (0.43) | POLBKDM4EALDH1A1GPR119BCHE | |
| SCHEMBL29831328 | 0.77 | PARP1 (0.59) | SLC22A12POLBGPR119BUB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745134-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3703692-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025016323-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20210179607-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3787612-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3703692-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179607-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | SLC22A12 1468/4885MET 3956/4885POLB 3003/4885 |
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | SLC22A12 618/4885MET 555/4885POLB 4573/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | SLC22A12 1054/4885MET 924/4885POLB 4496/4885 |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | SLC22A12 3853/4885MET 2884/4885POLB 1519/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | SLC22A12 1955/4885MET 23/4885POLB 2748/4885 |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | SLC22A12 1804/4885MET 4158/4885POLB 2689/4885 |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, CD47, GLI1 | SLC22A12 3064/4885MET 240/4885POLB 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.